JP2015027980A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015027980A5 JP2015027980A5 JP2013216031A JP2013216031A JP2015027980A5 JP 2015027980 A5 JP2015027980 A5 JP 2015027980A5 JP 2013216031 A JP2013216031 A JP 2013216031A JP 2013216031 A JP2013216031 A JP 2013216031A JP 2015027980 A5 JP2015027980 A5 JP 2015027980A5
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- ophthalmic
- phytoalexin
- treatment according
- eye drop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000858 Cyclodextrin Polymers 0.000 claims 4
- 239000003889 eye drop Substances 0.000 claims 4
- 229930014565 phytoalexin Natural products 0.000 claims 4
- 239000000280 phytoalexin Substances 0.000 claims 4
- 150000001857 phytoalexin derivatives Chemical class 0.000 claims 4
- 206010029113 Neovascularisation Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N 501-36-0 Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000003464 Asthenopia Diseases 0.000 claims 1
- 206010048964 Carotid artery occlusion Diseases 0.000 claims 1
- 208000002765 Choroid Disease Diseases 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000009745 Eye Disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010018987 Haemorrhage Diseases 0.000 claims 1
- 206010020675 Hypermetropia Diseases 0.000 claims 1
- 210000000554 Iris Anatomy 0.000 claims 1
- 208000002780 Macular Degeneration Diseases 0.000 claims 1
- 206010051058 Macular hole Diseases 0.000 claims 1
- 208000001491 Myopia Diseases 0.000 claims 1
- 208000004644 Retinal Vein Occlusion Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 1
- 206010047571 Visual impairment Diseases 0.000 claims 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 201000009310 astigmatism Diseases 0.000 claims 1
- 201000004569 blindness Diseases 0.000 claims 1
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 201000007717 corneal ulcer Diseases 0.000 claims 1
- 230000003247 decreasing Effects 0.000 claims 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 1
- 201000006318 hyperopia Diseases 0.000 claims 1
- 230000004305 hyperopia Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000004379 myopia Effects 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- 201000010041 presbyopia Diseases 0.000 claims 1
- 235000010949 resVida® Nutrition 0.000 claims 1
- 230000002207 retinal Effects 0.000 claims 1
- 235000020945 retinal Nutrition 0.000 claims 1
- 239000011604 retinal Substances 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 235000018991 trans-resveratrol Nutrition 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- GDSRMADSINPKSL-HSEONFRVSA-N γ-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013216031A JP2015027980A (ja) | 2013-06-25 | 2013-10-17 | 眼疾患の点眼治療薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013132415 | 2013-06-25 | ||
| JP2013132415 | 2013-06-25 | ||
| JP2013216031A JP2015027980A (ja) | 2013-06-25 | 2013-10-17 | 眼疾患の点眼治療薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015027980A JP2015027980A (ja) | 2015-02-12 |
| JP2015027980A5 true JP2015027980A5 (ko) | 2016-11-24 |
Family
ID=52491961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013216031A Pending JP2015027980A (ja) | 2013-06-25 | 2013-10-17 | 眼疾患の点眼治療薬 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2015027980A (ko) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11331282B2 (en) | 2017-06-23 | 2022-05-17 | TK Health Research, Co, Ltd. | Ophthalmic composition containing clathrated antioxidant substance, and use thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060111318A1 (en) * | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
-
2013
- 2013-10-17 JP JP2013216031A patent/JP2015027980A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2009003161A (es) | Antagonistas de dii4 para el tratamiento de trastornos vasculares e isquemicos | |
| WO2011151685A8 (en) | N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament | |
| JP2013528563A5 (ko) | ||
| MX2020007948A (es) | Medicamento para prevenir o tratar una enfermedad oftalmica asociada con neovascularizacion intraocular mejorada y/o permeabilidad vascular intraocular. | |
| Okhotsimskaya et al. | Aflibercept for the therapy of retinal diseases. A review of clinical studies | |
| Fasih et al. | A one-year follow-up study of ocular and systemic complications of intravitreal injection of bevacizumab (Avastin). | |
| JP2015027980A5 (ko) | ||
| TN2016000259A1 (en) | Salbutamol (albuterol) eye protective medicament. | |
| JP2013513606A5 (ko) | ||
| Chou et al. | Changes in corneal curvature after wearing the orthokeratology lens | |
| Mortensen | Corneal ectasia after PRK | |
| Santoro | Experiences of using Aflibercept in diabetic macular edema treatment: data from routine clinical practice | |
| Sooryadas et al. | Persistent pupillary membranes in a cat: A case report | |
| Kim et al. | Comparison of intravitreal bevacizumab alone injection and intravitreal combination low-dose bevacizumab-triamcinolone injection or diabetic macular edema | |
| Saib et al. | Progression of visual field defect in an unilateral glaucoma patient after an unilateral photorefractive keratectomy | |
| Mosaed | Comprehensive trabectome outcomes in surgery-naïve versus previously operated eyes | |
| Makarov et al. | Transepithelial photorefractive keratectomy for treatment of stromal corneal opacity in combination with hyperopia refraction and irregular astigmatism | |
| Baumal | Branch Retinal Vein Occlusion | |
| Martínez-de-la-Casa et al. | Post-laser in situ keratomileusis refractive changes induced by glaucoma in the absence of keratectasia | |
| Oshima | Full thickness macular hole: case report | |
| Lamas et al. | Coats Disease in Young Patient with Congenital Cataracts History | |
| Li | Unilateral fundus hemorrhage: case report | |
| Bandello et al. | Ocular Ischemic Syndrome | |
| Nowroozzadeh | Prostaglandin analogs may aggravate myopic regression after laser in situ keratomileusis | |
| Shchuko et al. | Transpupillary thermotherapy of the optic nerve as a method of choice in the treatment of the central retinal vein occlusion |